

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
Participants Enrolled	60	67	60	60	247
1. ACASI Required and Expected	371	468	389	400	1628
Completed	337 (90.8%)	461 (98.5%)	383 (98.5%)	383 (95.8%)	1564 (96.1%)
Not Completed	34 (9.2%)	7 (1.5%)	6 (1.5%)	17 (4.3%)	64 (3.9%)
2. Social Harms / Benefits Assessment Required and Expected	311	402	331	340	1384
Completed	308 (99.0%)	402 (100.0%)	331 (100.0%)	340 (100.0%)	1381 (99.8%)
Not Completed	3 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.2%)
3. Physical Exam Required and Expected	1017	1266	1055	1084	4422
Completed	1000 (98.3%)	1255 (99.1%)	1052 (99.7%)	1084 (100.0%)	4391 (99.3%)
Not Completed	17 (1.7%)	11 (0.9%)	3 (0.3%)	0 (0.0%)	31 (0.7%)
4. Pelvic Exam Required and Expected	431	534	450	457	1872
Completed	391 (90.7%)	525 (98.3%)	445 (98.9%)	453 (99.1%)	1814 (96.9%)
Not Completed	40 (9.3%)	9 (1.7%)	5 (1.1%)	4 (0.9%)	58 (3.1%)
5. Pregnancy Test Required and Expected	1017	1266	1051	1084	4418
Completed	1002 (98.5%)	1255 (99.1%)	1038 (98.8%)	1051 (97.0%)	4346 (98.4%)
Not Completed	15 (1.5%)	11 (0.9%)	13 (1.2%)	33 (3.0%)	72 (1.6%)
6. HIV-1 Test Required and Expected	1007	1262	1055	1081	4405
Completed	994 (98.7%)	1248 (98.9%)	1052 (99.7%)	1080 (99.9%)	4374 (99.3%)
Not Completed	13 (1.3%)	14 (1.1%)	3 (0.3%)	1 (0.1%)	31 (0.7%)
7. HSV-2 Antibody Storage Required and Expected	115	134	114	116	479
Completed	113 (98.3%)	131 (97.8%)	114 (100.0%)	116 (100.0%)	474 (99.0%)
Not Completed	2 (1.7%)	3 (2.2%)	0 (0.0%)	0 (0.0%)	5 (1.0%)
8. Hepatitis B Surface Antigen Test Required and Expected	60	67	60	60	247
Completed	60 (100.0%)	67 (100.0%)	60 (100.0%)	60 (100.0%)	247 (100.0%)
9. Blood Plasma Archive/Storage Required and Expected	371	469	391	400	1631
Completed	361 (97.3%)	461 (98.3%)	390 (99.7%)	400 (100.0%)	1612 (98.8%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
Not Completed	10 (2.7%)	8 (1.7%)	1 (0.3%)	0 (0.0%)	19 (1.2%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
10. Blood Chemistry Required and Expected	115	134	114	116	479
Completed	114 (99.1%)	131 (97.8%)	114 (100.0%)	116 (100.0%)	475 (99.2%)
Not Completed	1 (0.9%)	3 (2.2%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
11. Hematology Required and Expected	115	134	114	116	479
Completed	114 (99.1%)	131 (97.8%)	114 (100.0%)	116 (100.0%)	475 (99.2%)
Not Completed	1 (0.9%)	3 (2.2%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
12. Dried Blood Spot for PK Sample Storage Required and Expected (Truvada users only)	126	136	192	204	658
Completed	126 (100.0%)	136 (100.0%)	191 (99.5%)	199 (97.5%)	652 (99.1%)
Not Completed	0 (0.0%)	0 (0.0%)	1 (0.5%)	5 (2.5%)	6 (0.9%)
13. Rapid Test for Trichomonas Test Required and Expected	115	134	114	116	479
Completed	114 (99.1%)	134 (100.0%)	114 (100.0%)	116 (100.0%)	478 (99.8%)
Not Completed	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)
14. NAAT (Pelvic) for GC/CT Required and Expected	115	134	114	116	479
Completed	112 (97.4%)	129 (96.3%)	113 (99.1%)	116 (100.0%)	470 (98.1%)
Not Completed	3 (2.6%)	5 (3.7%)	1 (0.9%)	0 (0.0%)	9 (1.9%)
15. Vaginal PH Test Required and Expected	60	67	60	60	247
Completed	59 (98.3%)	67 (100.0%)	60 (100.0%)	60 (100.0%)	246 (99.6%)
Not Completed	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
16. Vaginal Swabs for Microbiota	265	335	283	289	1172
Completed	224 (84.5%)	329 (98.2%)	279 (98.6%)	282 (97.6%)	1114 (95.1%)
Not Completed	41 (15.5%)	6 (1.8%)	4 (1.4%)	7 (2.4%)	58 (4.9%)
17. Vaginal Gram Stain Required and Expected	371	469	391	400	1631
Completed	327 (88.1%)	458 (97.7%)	386 (98.7%)	393 (98.3%)	1564 (95.9%)
Not Completed	44 (11.9%)	11 (2.3%)	5 (1.3%)	7 (1.8%)	67 (4.1%)
18. Vaginal Swab for Biomarkers Required and Expected	371	469	391	400	1631
Completed	328 (88.4%)	457 (97.4%)	383 (98.0%)	382 (95.5%)	1550 (95.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
Not Completed	43 (11.6%)	12 (2.6%)	8 (2.0%)	18 (4.5%)	81 (5.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
19. CVL Supernatant for Biomarker Required and Expected	371	469	391	400	1631
Completed	328 (88.4%)	456 (97.2%)	383 (98.0%)	382 (95.5%)	1549 (95.0%)
Not Completed	43 (11.6%)	13 (2.8%)	8 (2.0%)	18 (4.5%)	82 (5.0%)
20. CVL Pellet for Biomarker Required and Expected	371	469	391	400	1631
Completed	328 (88.4%)	456 (97.2%)	383 (98.0%)	382 (95.5%)	1549 (95.0%)
Not Completed	43 (11.6%)	13 (2.8%)	8 (2.0%)	18 (4.5%)	82 (5.0%)
21. Cervical Swab for Biomarkers Required and Expected	371	469	391	400	1631
Completed	328 (88.4%)	456 (97.2%)	383 (98.0%)	382 (95.5%)	1549 (95.0%)
Not Completed	43 (11.6%)	13 (2.8%)	8 (2.0%)	18 (4.5%)	82 (5.0%)
22. Cervical Cytobrush for Flow Cytometry Required and Expected (Zimbabwe only)	0	0	0	400	400
Completed	0 (-%)	0 (-%)	0 (-%)	387 (96.8%)	387 (96.8%)
Not Completed	0 (-%)	0 (-%)	0 (-%)	13 (3.3%)	13 (3.3%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.